Zoetis Inc. (ZTS) Price History:-51.22%(TTM)
The price cagr for Zoetis Inc. (ZTS) is -51.22% over the latest trailing 12-month period. The comparable SPY value is +20.75%. Year-to-date price return is -35.24%. Price CAGR uses adjusted close price history and excludes dividends.
Current Price
$81.55
$-0.66 (-0.80%)
Previous Close: $82.20
Today's Trading
- Open
- $82.36
- Day High
- $82.98
- Day Low
- $81.29
- Volume
- 3.23M
- Avg Volume
- N/A
52-Week Position
10%
of the 52-week price range
- From 52-week high
- -51.70%
- From 52-week low
- +12.66%
52-Week Price Range
52-Week Low
$72.38
May 15, 2026
Current Price
$81.55
10% of range
52-Week High
$168.83
Jun 12, 2025
Price Returns by Period
1 Day
-0.80%
7 Days
+5.10%
30 Days
+6.36%
YTD
-35.24%
1 Year
-51.20%
vs 52W High
-51.70%
ZTS Price Chart
Long-Term Performance (CAGR)
Price CAGR (3Y)
-20.61%
Price CAGR (5Y)
-14.85%
Total Return CAGR (3Y)
-19.64%
Total Return CAGR (5Y)
-13.98%
CAGR (Compound Annual Growth Rate) shows the annualized return over the specified period. Total Return includes dividends reinvested.
Key Price Statistics
| Current Price | $81.55 |
| Previous Close | $82.20 |
| Day Range | $81.29 - $82.98 |
| 52-Week Range | $72.38 - $168.83 |
| Volume | 3.23M |
| Average Volume | N/A |
| Market Cap | $34.20B |
| % from 52W High | -51.70% |
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck